The US FDA has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid.

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted treatment approved for adults with this rare autoimmune blistering disease.

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with systemic corticosteroids, Sanofi and Regeneron announced. The FDA’s ...